Clinical Trial Update: Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial evaluating intracranial TGFβR2KO/IL13Rα2 CAR T-cells for recurrent glioblastoma and IDH-mutant astrocytoma (WHO grade 3/4). The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Idh-mutant Who
• Glioblastoma

Drugs mentioned

• TGFβR2KO IL13Rα2 CAR T-Cells (TGFβR2 knockout IL-13 receptor alpha-2 CAR T-cell)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4 | Phase 1 | Status: RECRUITING